Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) shares were down 21.7% on Monday . The stock traded as low as $0.4520 and last traded at $0.4520. Approximately 308 shares changed hands during trading, a decline of 95% from the average session volume of 6,020 shares. The stock had previously closed at $0.5770.
Avenue Therapeutics Trading Down 21.7%
The firm has a market cap of $1.49 million, a P/E ratio of 0.02 and a beta of -0.20. The business’s fifty day simple moving average is $0.31 and its 200-day simple moving average is $0.32.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.
The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.
Featured Stories
- Five stocks we like better than Avenue Therapeutics
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
